179 related articles for article (PubMed ID: 28632395)
1. Design, synthesis and multitarget biological profiling of second-generation anti-Alzheimer rhein-huprine hybrids.
Pérez-Areales FJ; Betari N; Viayna A; Pont C; Espargaró A; Bartolini M; De Simone A; Rinaldi Alvarenga JF; Pérez B; Sabate R; Lamuela-Raventós RM; Andrisano V; Luque FJ; Muñoz-Torrero D
Future Med Chem; 2017 Jun; 9(10):965-981. PubMed ID: 28632395
[TBL] [Abstract][Full Text] [Related]
2. Shogaol-huprine hybrids: dual antioxidant and anticholinesterase agents with β-amyloid and tau anti-aggregating properties.
Pérez-Areales FJ; Di Pietro O; Espargaró A; Vallverdú-Queralt A; Galdeano C; Ragusa IM; Viayna E; Guillou C; Clos MV; Pérez B; Sabaté R; Lamuela-Raventós RM; Luque FJ; Muñoz-Torrero D
Bioorg Med Chem; 2014 Oct; 22(19):5298-307. PubMed ID: 25156301
[TBL] [Abstract][Full Text] [Related]
3. Amiridine-piperazine hybrids as cholinesterase inhibitors and potential multitarget agents for Alzheimer's disease treatment.
Makhaeva GF; Lushchekina SV; Kovaleva NV; Yu Astakhova T; Boltneva NP; Rudakova EV; Serebryakova OG; Proshin AN; Serkov IV; Trofimova TP; Tafeenko VA; Radchenko EV; Palyulin VA; Fisenko VP; Korábečný J; Soukup O; Richardson RJ
Bioorg Chem; 2021 Jul; 112():104974. PubMed ID: 34029971
[TBL] [Abstract][Full Text] [Related]
4. Bis-Amiridines as Acetylcholinesterase and Butyrylcholinesterase Inhibitors:
Makhaeva GF; Kovaleva NV; Boltneva NP; Rudakova EV; Lushchekina SV; Astakhova TY; Serkov IV; Proshin AN; Radchenko EV; Palyulin VA; Korabecny J; Soukup O; Bachurin SO; Richardson RJ
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164325
[TBL] [Abstract][Full Text] [Related]
5. Novel huprine derivatives with inhibitory activity toward β-amyloid aggregation and formation as disease-modifying anti-Alzheimer drug candidates.
Viayna E; Gómez T; Galdeano C; Ramírez L; Ratia M; Badia A; Clos MV; Verdaguer E; Junyent F; Camins A; Pallàs M; Bartolini M; Mancini F; Andrisano V; Arce MP; Rodríguez-Franco MI; Bidon-Chanal A; Luque FJ; Camps P; Muñoz-Torrero D
ChemMedChem; 2010 Nov; 5(11):1855-70. PubMed ID: 20859987
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and multitarget biological profiling of a novel family of rhein derivatives as disease-modifying anti-Alzheimer agents.
Viayna E; Sola I; Bartolini M; De Simone A; Tapia-Rojas C; Serrano FG; Sabaté R; Juárez-Jiménez J; Pérez B; Luque FJ; Andrisano V; Clos MV; Inestrosa NC; Muñoz-Torrero D
J Med Chem; 2014 Mar; 57(6):2549-67. PubMed ID: 24568372
[TBL] [Abstract][Full Text] [Related]
7. Huprine Y - Tryptophan heterodimers with potential implication to Alzheimer's disease treatment.
Mezeiova E; Hrabinova M; Hepnarova V; Jun D; Janockova J; Muckova L; Prchal L; Kristofikova Z; Kucera T; Gorecki L; Chalupova K; Kunes J; Hroudova J; Soukup O; Korabecny J
Bioorg Med Chem Lett; 2021 Jul; 43():128100. PubMed ID: 33984470
[TBL] [Abstract][Full Text] [Related]
8. Development of 2-Methoxyhuprine as Novel Lead for Alzheimer's Disease Therapy.
Mezeiova E; Korabecny J; Sepsova V; Hrabinova M; Jost P; Muckova L; Kucera T; Dolezal R; Misik J; Spilovska K; Pham NL; Pokrievkova L; Roh J; Jun D; Soukup O; Kaping D; Kuca K
Molecules; 2017 Jul; 22(8):. PubMed ID: 28788095
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological assessment of racemic benzochromenopyrimidinetriones as promising agents for Alzheimer's disease therapy.
Dgachi Y; Martin H; Bonet A; Chioua M; Iriepa I; Moraleda I; Chabchoub F; Marco-Contelles J; Ismaili L
Future Med Chem; 2017 May; 9(8):715-721. PubMed ID: 28504912
[TBL] [Abstract][Full Text] [Related]
10. Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.
Di Pietro O; Pérez-Areales FJ; Juárez-Jiménez J; Espargaró A; Clos MV; Pérez B; Lavilla R; Sabaté R; Luque FJ; Muñoz-Torrero D
Eur J Med Chem; 2014 Sep; 84():107-17. PubMed ID: 25016233
[TBL] [Abstract][Full Text] [Related]
11. Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases.
Galdeano C; Viayna E; Sola I; Formosa X; Camps P; Badia A; Clos MV; Relat J; Ratia M; Bartolini M; Mancini F; Andrisano V; Salmona M; Minguillón C; González-Muñoz GC; Rodríguez-Franco MI; Bidon-Chanal A; Luque FJ; Muñoz-Torrero D
J Med Chem; 2012 Jan; 55(2):661-9. PubMed ID: 22185619
[TBL] [Abstract][Full Text] [Related]
12. 1-Benzylpyrrolidine-3-amine-based BuChE inhibitors with anti-aggregating, antioxidant and metal-chelating properties as multifunctional agents against Alzheimer's disease.
Wichur T; Więckowska A; Więckowski K; Godyń J; Jończyk J; Valdivieso ÁDR; Panek D; Pasieka A; Sabaté R; Knez D; Gobec S; Malawska B
Eur J Med Chem; 2020 Feb; 187():111916. PubMed ID: 31812794
[TBL] [Abstract][Full Text] [Related]
13. Rational design, synthesis and biological screening of triazine-triazolopyrimidine hybrids as multitarget anti-Alzheimer agents.
Jameel E; Meena P; Maqbool M; Kumar J; Ahmed W; Mumtazuddin S; Tiwari M; Hoda N; Jayaram B
Eur J Med Chem; 2017 Aug; 136():36-51. PubMed ID: 28478343
[TBL] [Abstract][Full Text] [Related]
14. From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects.
Pont C; Ginex T; Griñán-Ferré C; Scheiner M; Mattellone A; Martínez N; Arce EM; Soriano-Fernández Y; Naldi M; De Simone A; Barenys M; Gómez-Catalán J; Pérez B; Sabate R; Andrisano V; Loza MI; Brea J; Bartolini M; Bolognesi ML; Decker M; Pallàs M; Luque FJ; Muñoz-Torrero D
Eur J Med Chem; 2021 Dec; 225():113779. PubMed ID: 34418785
[TBL] [Abstract][Full Text] [Related]
15. Increasing Polarity in Tacrine and Huprine Derivatives: Potent Anticholinesterase Agents for the Treatment of Myasthenia Gravis.
Galdeano C; Coquelle N; Cieslikiewicz-Bouet M; Bartolini M; Pérez B; Clos MV; Silman I; Jean L; Colletier JP; Renard PY; Muñoz-Torrero D
Molecules; 2018 Mar; 23(3):. PubMed ID: 29534488
[TBL] [Abstract][Full Text] [Related]
16. New cyclopentaquinoline hybrids with multifunctional capacities for the treatment of Alzheimer's disease.
Czarnecka K; Girek M; Maciejewska K; Skibiński R; Jończyk J; Bajda M; Kabziński J; Sołowiej P; Majsterek I; Szymański P
J Enzyme Inhib Med Chem; 2017 Dec; 33(1):158-170. PubMed ID: 29210299
[TBL] [Abstract][Full Text] [Related]
17. 9-Substituted acridine derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors possessing antioxidant activity for Alzheimer's disease treatment.
Makhaeva GF; Lushchekina SV; Boltneva NP; Serebryakova OG; Rudakova EV; Ustyugov AA; Bachurin SO; Shchepochkin AV; Chupakhin ON; Charushin VN; Richardson RJ
Bioorg Med Chem; 2017 Nov; 25(21):5981-5994. PubMed ID: 28986116
[TBL] [Abstract][Full Text] [Related]
18. New (benz)imidazolopyridino tacrines as nonhepatotoxic, cholinesterase inhibitors for Alzheimer disease.
Boulebd H; Ismaili L; Martin H; Bonet A; Chioua M; Marco Contelles J; Belfaitah A
Future Med Chem; 2017 May; 9(8):723-729. PubMed ID: 28485637
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of novel 5,6,7-trimethoxyflavone-6-chlorotacrine hybrids as potential multifunctional agents for the treatment of Alzheimer's disease.
Liao S; Deng H; Huang S; Yang J; Wang S; Yin B; Zheng T; Zhang D; Liu J; Gao G; Ma J; Deng Z
Bioorg Med Chem Lett; 2015 Apr; 25(7):1541-5. PubMed ID: 25724825
[TBL] [Abstract][Full Text] [Related]
20. New huprine derivatives functionalized at position 9 as highly potent acetylcholinesterase inhibitors.
Ronco C; Foucault R; Gillon E; Bohn P; Nachon F; Jean L; Renard PY
ChemMedChem; 2011 May; 6(5):876-88. PubMed ID: 21344648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
